Asieris(SH:688176) Xin Lang Zheng Quan·2025-10-28 01:35Core Insights - On October 27, Yahui Pharmaceutical's stock rose by 1.43%, with a trading volume of 46.12 million yuan [1] - The company reported a financing buy-in of 3.43 million yuan and a financing repayment of 4.61 million yuan, resulting in a net financing outflow of 1.18 million yuan on the same day [1] - As of October 27, the total margin balance for Yahui Pharmaceutical was 194 million yuan, representing 4.49% of its market capitalization [1] Financing Overview - On October 27, Yahui Pharmaceutical had a financing buy-in of 3.43 million yuan, with a current financing balance of 194 million yuan, which is above the 70th percentile of the past year [1] - The company had no short-selling activity on October 27, with a short-selling balance of 0 yuan, indicating a high level of short-selling availability compared to the past year [1] Company Profile - Yahui Pharmaceutical, established on March 16, 2010, is located in the Pudong New Area of Shanghai and was listed on January 7, 2022 [1] - The company's main business involves the research, production, and sales of innovative drugs, with 96.34% of its revenue coming from anti-tumor products [1] Shareholder Information - As of June 30, the number of shareholders for Yahui Pharmaceutical was 25,500, an increase of 2.09% from the previous period [2] - The average number of circulating shares per shareholder decreased by 2.05% to 14,857 shares [2] - For the first half of 2025, Yahui Pharmaceutical reported a revenue of 130 million yuan, a year-on-year increase of 61.80%, while the net profit attributable to the parent company was -162 million yuan, an increase of 11.84% year-on-year [2] Institutional Holdings - As of June 30, 2025, the fourth largest circulating shareholder of Yahui Pharmaceutical was Penghua Medical Technology Stock A, holding 6.54 million shares, an increase of 891,300 shares from the previous period [2]